Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries is currently trading at Rs 741.05, up by 22.90 points or 3.19% from its previous closing of Rs 718.15 on the BSE.

The scrip opened at Rs 727.60 and has touched a high and low of Rs 752.10 and Rs 727.60 respectively. So far 66545 shares were traded on the counter.

The BSE group 'A' stock of face value Re 1 has touched a 52 week high of Rs 775.90 on 20-Dec-2012 and a 52 week low of Rs 532.10 on 07-Feb-2012.

Last one week high and low of the scrip stood at Rs 729.35 and Rs 705.05 respectively. The current market cap of the company is Rs 74561.90 crore.

The promoters holding in the company stood at 63.68% while Institutions and Non-Institutions held 25.90% and 10.42% respectively.

Sun Pharmaceuticals Industries’ subsidiary has received US Food and Drug Administration (FDA) approval for its Abbreviated New Drug Application (ANDA) for generic version of Doxil, Doxorubicin HCI Liposome Injection USP 2mg/ml, packaged in 20mg/10ml and 50mg/25ml single use vials.

The generic Doxorubicin HCI Liposome Injection USP 2mg/ml is therapeutically equivalent to Doxil Liposome Injection 2mg/ml of Janssen Research and Development, LLC. Doxorubicin HCI Liposome Injection is used to treat patients with ovarian cancer that has progressed of recurred after platinum-based chemotherapy.

Sun Pharmaceuticals Industries is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world